Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery
Status:
Suspended
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Rheumatic heart valve diseases are prevalent among the young people in Egypt secondary to the
socioeconomic conditions. The goal of anesthetic management of these patients is maintenance
of sinus rhythm, systemic blood pressure, preload, coronary perfusion, and cardiac output.
Many women still prefer general anesthesia rather than regional techniques at the author's
country.
The pharmacological modifications of the sympathetic response to tracheal intubation and
surgical stimulation using opioids have adverse effects on the neonatal outcome after
cesarean delivery. The authors have demonstrated in their previous studies the safety of both
perioperative infusion of both of ketorolac and lidocaine in the attenuation of the
hemodynamic and hormonal responses of tracheal intubation and surgery during cesarean
delivery with favorable neonatal outcome and without added risk of perioperative bleeding.
Therefore, the authors reported successful anesthetic management of a parturient with
infective endocarditis on top of rheumatic mitral valve disease with use of
paracetamol-lidocaine-ketorolac-propofol anesthesia.
The investigators hypothesize that the perioperative use of ketorolac-lidocaine would reduce
the maternal hemodynamic responses to intubation and surgery without any harmful effects on
mother or baby during uncomplicated cesarean delivery in the parturients with valvular hear
diseases.
The investigators are aiming to compare the effects of ketorolac-lidocaine and fentanyl on
surgical stress responses, intraoperative fentanyl and vasoactive drugs consumption and
neonatal outcome during cesarean delivery in the parturients with valvular hear diseases.